| Literature DB >> 27192128 |
Susana Suely Rodrigues Milhomem-Paixão1, Maria Luiza Fascineli2, Mariana Matos Roll3, João Paulo Figueiró Longo2, Ricardo Bentes Azevedo2, Julio Cesar Pieczarka1, Hugo Leonardo Crisóstomo Salgado4, Alberdan Silva Santos4, Cesar Koppe Grisolia3.
Abstract
Andirobeira is an Amazonian tree, the seeds of which produce a commercially valuable oil that is used in folk medicine and in the cosmetic industry. Andiroba oil contains components with anti-inflammatory, cicatrizing and insect-repellant actions. However, virtually nothing is known of the safety of this oil for humans. The aim of this work was therefore to investigate the hematotoxicity, genotoxicity and mutagenicity of andiroba oil using the comet and micronucleus assays, and to assess its antioxidant properties and lipidome as a means of addressing safety issues. For the experiments, andiroba oil was administered by gavage for 14 consecutive days in nulliparous female Swiss mice randomly distributed in four groups: negative control and three doses of oil (500, 1000 and 2000 mg/kg/day). These doses were chosen based on recommendations of the OECD guideline no. 474 (1997). GC/MS was used to investigate the free fatty acid, cholesterol and triterpene content of andiroba oil in a lipidomic analysis. No clinical or behavioral alterations were observed throughout the period of treatment, and exposure to andiroba oil at the doses and conditions used here did not result in hematotoxic, genotoxic or mutagenic effects. Tests in vitro showed that oil sample 3 from southwestern of Brazilian Amazon had a high antioxidant capacity that may protect biological systems from oxidative stress, although this activity remains to be demonstrated in vivo.Entities:
Year: 2016 PMID: 27192128 PMCID: PMC4910557 DOI: 10.1590/1678-4685-GMB-2015-0098
Source DB: PubMed Journal: Genet Mol Biol ISSN: 1415-4757 Impact factor: 1.771
Samples, localities and periods of collection of andiroba seeds and the concentration of oil causing a 50% reduction in the DPPH radical (EC50).
| Samples | Mesoregion | Municipality | Geographical coordinates | Collection period | EC50 (μL/mL) |
|---|---|---|---|---|---|
| SE1 | Southeast | Nova Ipixuna | S 04° 48′ 30.1″ W 049° 21′ 42.8″ | 16-20/4/12 | 86.62 |
| SE2 | Jacundá | S 04° 27′ 03.0″ W 049° 06′ 59.5″ | 16-20/4/12 | 151.0 | |
| SE3 | São Miguel do Guamá | S 01° 35′ 28.5″ W 047° 34′ 39.5″ | 3-7/5/2012 | 126.7 | |
| NE1 | Northeast | Abaetetuba | S 01° 43′ 04″ W 048° 52′ 58″ | 3-7/5/2012 | 2305 |
| NE2 | Acará | S 01° 58′ 25.9″ W 048° 18′ 49.5″ | 3-7/5/2012 | 302.0 | |
| NE3 | Cametá | S 02° 14′ 40.0″ W 049° 29′ 45.0″ | 3-7/5/2012 | 204.3 | |
| LAM1 | Lower Amazon | Santarém | S 02° 24′ 52″ W 054° 42′ 36.0″ | 25-29/3/2012 | 43.56 |
| LAM2 | Oriximiná | S 01° 30′ 55.3″ W 055° 46′ 52.0″ | 25-29/3/2012 | 150.7 | |
| LAM3 | Óbidos | S 01° 39′ 21.5″ W 055° 37′ 15.9″ | 25-29/3/2012 | 45.20 | |
| MAR1 | Marajó | Curralinho | S 01° 45′ 59.1″ W 049° 49′ 45.2″ | 12/4; 23/5 and 24/7/2012 | 468.9 |
| MAR2 | Salvaterra | S 00° 48′ 02.0″ W 048° 32′ 01.0″ | 12/4; 23/5 and 24/7/2012 | 90.23 | |
| MAR3 | Breves | S 01° 38′ 17.9″ W 050° 27′ 99.5″ | 12/4; 23/5 and 24/7/2012 | 1894 | |
| MTR1 | Metropolitan | Santa Isabel do Pará | S 01° 21′ 12.4″ W 048° 08′ 37.3″ | 29/3-1/4/2012 | 326.3 |
| MTR2 | Castanhal | S 01° 17′ 49.5″ W 047° 55′ 19.7″ | 29/3-1/4/2012 | 559.3 | |
| MTR3 | Bujarú | S 01° 35′ 46.3″ W 047° 57′ 32.9″ | 29/3-1/4/2012 | 252.6 | |
| SW1 | Southwest | Porto de Moz | S 01° 45′ 00″ W 052° 14′ 15.0″ | 25-29/3/2012 | 425.4 |
| SW2 | Medicilândia | S 03° 23′ 59.0″ W 052° 53′ 36.8″ | 12/3-24/4/2012 | 1181 | |
| SW3 | Uruará | S 03° 58′ 31.7″ W 053° 37′ 32.1″ | 12/3-24/4/2012 | 59.95 | |
| SW4 | Itaituba | S 04° 16′ 34.0″ W 055° 59′ 01.0″ | 29/3-5/4/2012 | 150.0 | |
| SW5 | Jacareacanga | S 06° 13′ 20.0″ W 057° 45′ 10.0″ | 29/3-5/4/2012 | 100.4 | |
| SW6 | Aveiro | S 03° 50′ 30.0″ W 055° 28′ 32.7″ | 29/3-5/4/2012 | 106.7 | |
| IANA | 8913 | ||||
| AMAZON | 204.8 |
S – South, W – West. EC50: minimum concentration required to reduce 50% of DPPH.
Commercial samples: Amazon Ervas and Iana® D'amazônia.
Profile of fatty acids, steroids and triterpenes present in two samples (SW3-1 and SW3-2) of andiroba oil.
| Component | Peak retention time (min) | Retention index | Oil profile | SW3-1 | SW3-2 |
|---|---|---|---|---|---|
| Lipids 1 (%) | Lipids 2 (%) | ||||
| Fatty acids | 15.52 | 1899 | Miristic acid | 0.07 ± 0.03 | 0.13 ± 0.02 |
| 17.54 | 2027 | Palmitic acid | 37.95 ± 0.63 | 32.21 ± 0.94 | |
| 17.86 | 2048 | Palmitoleic acid | 0.07 ± 0.12 | 0.81 ± 0.07 | |
| 20.49 | 2234 | Oleic acid | 55.23 ± 0.43 | 41.92 ± 0.52 | |
| 21.37 | 2301 | Linoleic acid | 4.21 ± 0.34 | 7.63 ± 0.36 | |
| 21.58 | 2318 | Stearic acid | 0.03 ± 0.06 | 14.53 ± 0.75 | |
| 22.93 | 2428 | Arachidic acid | 1.07 ± 0.19 | 2.12 ± 0.39 | |
| 25.52 | 2664 | Behenic acid | 0.28 ± 0.07 | 0.43 ± 0.06 | |
| 27.73 | 2894 | Lignoceric acid | 0.17 ± 0.06 | 0.25 ± 0.01 | |
| Steroids | 28.59 | Ns | Squalene | 0.43 ± 0.61 | - |
| 30.86 | Ns | Stigmasterol | 0.11 ± 0.04 | - | |
| 31.87 | Ns | Cholesterol | 0.07 ± 0.02 | - | |
| Triterpenes | 33.11 | Ns | Epoxygedunnin | 0.08 ± 0.02 | - |
| 33.64 | Ns | 1,3-Dipalmitin | 0.09 ± 0.02 | - | |
| 33.94 | Ns | Deoxylactone-derivative | 0.13 ± 0.02 | - | |
| 35.92 | Ns | Deacetylgedunin | 0.04 ± 0.01 | - | |
| 36.40 | Ns | Epoxydeacetylgedunin | 0.06 ± 0.03 | - |
Ns = not simulated (requires hydrocarbons with a carbon number > 30),
Tentative identification.
Lipids 1 = fermented seeds (extracted by oil dripping). Lipids 2 = non-fermented seeds (extracted with solvent). The values are the mean ± SD of chromatographic quantifications. Retention Index: relative retention-time of a compound within the chromatograph according to its chromatographic properties. SW3-1 and SW3-2 means two chromatographic analysis of same sample.
Absolute and relative weights of mouse organs after treatment with andiroba oil.
| Andiroba oil (mg/kg/day) | ||||
|---|---|---|---|---|
| Negative control | 500 | 1000 | 2000 | |
| Absolute weight | ||||
| Liver | 1.82 ± 0.29 | 1.96 ± 0.31 | 1.86 ± 0.17 | 2.16 ± 0.30 |
| Spleen | 0.15 ± 0.08 | 0.15 ± 0.02 | 0.13 ± 0.01 | 0.13 ± 0.02 |
| Right kidney | 0.17 ± 0.02 | 0.18 ± 0.02 | 0.17 ± 0.02 | 0.20 ± 0.02 |
| Left kidney | 0.18 ± 0.02 | 0.18 ± 0.02 | 0.17 ± 0.01 | 0.19 ± 0.02 |
| Relative weight | ||||
| Liver | 4.81 ± 0.19 | 5.10 ± 0.35 | 5.26 ± 0.51 | 5.29 ± 0.45 |
| Spleen | 0.39 ± 0.16 | 0.40 ± 0.08 | ± 0.08 | 0.33 ± 0.05 |
| Right kidney | 0.46 ± 0.05 | 0.48 ± 0.03 | 0.48 ± 0.05 | 0.49 ± 0.05 |
| Left kidney | ± 0.05 | 0.47 ± 0.04 | 0.48 ± 0.05 | 0.48 ± 0.06 |
The relative weight is expressed in relation to the final body weight of each animal. The values are the mean ± SD (n = 6 animals/group) and were analyzed by ANOVA or the Kruskal-Wallis test, depending on the normality of the data distribution. There were no significant differences between the responses to andiroba oil and the negative control, or among the doses of oil tested.
Figure 1Comet test. The doses of andiroba oil are in mg/kg/day. NC – negative control. The columns represent the mean ± SD and were analyzed by ANOVA. There were no significant differences between the responses to andiroba oil and the negative control, or among the doses of oil tested.
Frequency of micronuclei after treatment with andiroba oil.
| Andiroba oil (mg/kg/day) | ||||
|---|---|---|---|---|
| Parameter | Negative control | 500 | 1000 | 2000 |
| MN-PCE (number) | 1.66 ± 2.42 | 2 ± 2.09 | 1.16 ± 1.60 | 2.5 ± 1.22 |
| MN-PCE (%) | 8.33 ± 12.11 | 10.00 ± 10.49 | 5.83 ± 8.01 | 12.50 ± 6.12 |
| PCE/NCE ratio | 1.77 ± 0.57 | 2.39 ± 0.60 | 2.10 ± 0.63 | 2.29 ± 0.42 |
MN – micronuclei, NCE – normochromatic erythrocytes, PCE – polychromatic erythrocytes. The values represent the mean ± SD and were analyzed by ANOVA. There were no significant differences between the responses to andiroba oil and the negative control, or among the doses of oil tested.
Erythrocyte, leukocyte and platelet counts and characteristics after treatment with andiroba oil.
| Andiroba oil (mg/kg/day) | ||||
|---|---|---|---|---|
| Parameters | Negative control | 500 | 1000 | 2000 |
| Erythrocytes | ||||
| RBC x 106/μL | 8.80 ± 0.35 | 8.93 ± 0.40 | 9.04 ± 0.29 | 8.57 ± 0.38 |
| HGB (g/dL) | 12.48 ± 0.45 | 12.50 ± 0.41 | 12.65 ± 0.40 | 12.07 ± 0.42 |
| HCT (%) | 32.23 ± 1.22 | 32.58 ± 1.12 | 32.75 ± 0.91 | 31.38 ± 1.05 |
| MCV (fL) | 36.7 ± 0.69 | 36.5 ± 0.72 | 36.2 ± 0.53 | 36.6 ± 0.64 |
| MCH (pg) | 14.2 ± 0.3 | 14.0 ± 0.5 | 14.0 ± 0.2 | 14.1 ± 0.2 |
| MCHC (g/dL) | 38.7 ± 0.41 | 38.4 ± 0.56 | 38.6 ± 0.48 | 38.5 ± 0.31 |
| RDW (%) | 13.57 ± 0.69 | 14.37 ± 1.13 | 14.17 ± 0.83 | 13.62 ± 0.78 |
| Leukocytes | ||||
| WBC x 103/μL | 2.23 ± 1.12 | 2.32 ± 1.16 | 2.53 ± 1.13 | 1.78 ± 0.75 |
| W-SCR (%) | 71.57 ± 9.24 | 71.45 ± 16.52 | 75.95 ± 10.58 | 76.38 ± 9.21 |
| W-MCR (%) | 27.78 ± 8.41 | 28.00 ± 16.16 | 23.57 ± 10.27 | 22.38 ± 7.28 |
| W-LCR (%) | 0.65 ± 1.02 | 0.38 ± 0.52 | 0.48 ± 0.68 | 1.23 ± 2.88 |
| Platelets | ||||
| PLT x 103/mL | 1371 ± 207 | 1479 ± 248 | 1442 ± 231 | 1340 ± 295 |
| PDW (fL) | 7.02 ± 0.48 | 7.00 ± 0.20 | 6.80 ± 0.11 | 7.00 ± 0.17 |
| MPV (fL) | 6.53 ± 0.48 | 6.48 ± 0.31 | 6.42 ± 0.13 | 6.38 ± 0.19 |
| P-LCR (%) | 7.28 ± 3.27 | 7.04 ± 2.04 | 7.28 ± 1.05 | 6.10 ± 1.75 |
HCT – hematocrit, HGB – hemoglobin, MCH – mean corpuscular hemoglobin, MCHC – mean corpuscular hemoglobin concentration, MCV – mean corpuscular volume, MPV – mean platelet volume, PDW – platelet distribution width, PLT – platelets, P-LCR – platelet large cell ratio, RBC – red blood cells (erythrocytes), RDW – red cell distribution width, WBC – white blood cells (leukocytes), W-LCR – eosinophils, W-MCR – neutrophils + monocytes, W-SCR – lymphocytes, fL – femtoliter, g/dL – g/deciliter, pg – picogram. The values represent the mean ± SD and were analyzed by ANOVA. There were no significant differences between the responses to andiroba oil and the negative control, or among the doses of oil tested.